Table 3.
Multivariate analysis of the association between clinicopathological characteristics and overall survival.
| Variables | Parameters | Total (n) | OR | 95% CI | p-value |
|---|---|---|---|---|---|
| Age* | ≤61 years | 126 | 1 | Ref. | Ref. |
| >61 years | 107 | 1.45 | 1.09–1.93 | 0.01 | |
| Histology | Acinar | 119 | 1 | Ref. | Ref. |
| Mucinous | 5 | 0.77 | 0.27–2.20 | 0.63 | |
| Lepidic | 8 | 1.01 | 0.43–2.39 | 0.98 | |
| Papillary | 27 | 1.22 | 0.76–1.97 | 0.41 | |
| Solid | 74 | 1.91 | 1.36–2.68 | <0.0001 | |
| Loss of weight** | No | 105 | 1 | Ref. | Ref. |
| <10% | 81 | 1.11 | 0.80–1.53 | 0.55 | |
| >10% | 47 | 1.72 | 1.17–2.54 | 0.006 | |
| PS ECOG | 0 | 13 | 1 | Ref. | Ref |
| 1 | 122 | 1.64 | 0.78–3.46 | 0.16 | |
| 2 | 42 | 2.43 | 1.07–5.51 | 0.03 | |
| 3 or 4 | 56 | 6.28 | 2.80–14.08 | <0.0001 | |
| Metastasis at diagnosis | CNS | 74 | 1 | Ref. | Ref. |
| Other sites | 159 | 0.62 | 0.45–0.85 | 0.004 | |
| TKi_EGFR | Yes_WT | 13 | 1 | Ref. | Ref. |
| Yes_Mutated | 48 | 0.91 | 0.45–1.84 | 0.926 | |
| No_WT | 152 | 1.75 | 0.92–3.31 | 0.052 | |
| No_Mutated | 20 | 3.79 | 1.73–8.33 | 0.001 | |
| KRAS mutations | WT | 194 | 1 | Ref. | Ref. |
| Mutated | 39 | 2.93 | 1.94–4.42 | <0.0001 |
*Only patients diagnosed at stage IV were included in this analysis. n, number of patients; OR, odds ratio; 95% CI, 95% confidence interval; p-value: significance of Cox Regression; Ref., reference group; *age was categorized into two groups considering the average age of the entire series as the cutoff; **Loss of weight <10% and >10% of total body weight; PS ECOG, performance status ECOG (Eastern Cooperative Oncology Group); CNS, central nervous system; TKi_EGFR, combination of two variables (TKi treatment and EGFR mutation). Significant associations are indicated in bold.